Cisplatin, 5-FU

DRUG2 trials

Sponsors

AIO-Studien-gGmbH, University Hospital Schleswig-Holstein

Conditions

Esophageal CancerEsophageal Squamous Cell Cancer

Phase 2

Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer

CompletedNCT01787006

University Hospital Schleswig-HolsteinEsophageal Cancer

Start: 2011-09-30End: 2018-09-06Updated: 2020-03-10

Phase 3

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

TerminatedNCT01627379

AIO-Studien-gGmbHEsophageal Squamous Cell Cancer

Start: 2012-05-31End: 2017-05-31Target: 300Updated: 2018-03-02

Related Papers

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)

Strahlentherapie und Onkologie2020-06-1211 citations

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

2019-12-1682 citations

LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).

Journal of Clinical Oncology2014-05-204 citations